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Abstract
Background: Despite the rapid increase in research in China, little is known about the quality of
clinical trials conducted there.
Methods: A systematic review and critical appraisal of randomised controlled trials (RCTs)
conducted in China and published in 2004 was undertaken to describe their characteristics, assess
the quality of their reporting, and where possible, the quality of their conduct. Randomised
controlled trials in all disease areas and types of interventions, which took place in China and
included Chinese citizens were identified using PubMed and hand searching the Journal Series of
the Chinese Medical Association. Quality was assessed against a subset of criteria adapted from the
CONSORT statement.
Results: Three hundred and seven RCTs were included. One hundred and ninety-nine (64.8%)
failed to report methods of randomization and 254 (82.4%) did not mention blinding of either
participants or investigators. Reporting of baseline characteristics, primary outcome and length of
follow-up was inadequate in a substantial proportion of studies. Fewer than 11% of RCTs
mentioned ethical approval and only 18.0% adequately discussed informed consent. However,
dropout rates were very favourable with nearly 44% of trials reporting a zero dropout rate.
Conclusion: Reporting of RCTs in China requires substantial improvement to meet the targets of
the CONSORT statement. The conduct of Chinese RCTs cannot be directly inferred from the
standard of reporting; however without good reporting the methods of the trials cannot be clearly
ascertained.
Background
Randomised controlled trials (RCTs) are considered the
'gold standard' for assessing the effectiveness of pharma-
cological and other interventions in the field of medicine
[1-4]. They are widely accepted as the best research design
because they distribute both known and unknown prog-
nostic factors between treatment groups by the play of
chance [5-8] thereby minimizing the possibility that any
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ing the basis for valid statistical comparison [8].
However, RCTs vary in their methodological rigour, and it
is well known that poor quality studies tend to produce
systematically different results from larger, better quality
studies, often erroneously showing larger treatment
effects [9,10]. The conduct of studies cannot be assessed
without clear reporting. Many medical journals now
expect authors to adhere to internationally agreed stand-
ards of reporting thus allowing the reader to assess the
conduct of each trial [11]; this has assisted in raising the
standards of trial reporting in developed countries[12].
China is a developing country with the biggest population
in the world. Research in China has been rapidly gaining
momentum, but as yet there is no systematic evaluation of
the current standard of trials conducted there. Evaluations
of the quality of Chinese RCTs have been restricted to
selected journals or fields, and often a limited list of qual-
ity indicators [13-19]. In one example, a recently pub-
lished systematic review of the effectiveness of hyperbaric
oxygen using Chinese RCTs found that the published
papers reported inadequate information and were gener-
ally of poor quality [16].
We present a critical evaluation of randomised controlled
trials conducted in China and published in 2004. Our aim
was to describe their general characteristics, evaluate the
quality of their reporting, and evaluate their conduct
where adequately reported.
Methods
The study was carried out according to a pre-defined pro-
tocol.
Search strategy
Randomised controlled trials published in 2004 were
identified through two broad sources:
1. Using the PubMed database. PubMed includes
MEDLINE and OLDMEDLINE [20] but papers published
in many non-English Journals are not listed. We searched
PubMed for Chinese randomised controlled trials pub-
lished in 2004 using the textwords 'chin*' and the
PubMed filter for randomised controlled trials.
2. Since many of the main medical journals in China are
not indexed in PubMed, or in any electronic database, we
also accessed the online versions of each journal in the
Journal Series of the Chinese Medical Association. The
Journal Series of the Chinese Medical Association includes
71 journals, which comprise the main core medical jour-
nals in Mainland China and additionally the Chinese ver-
sion of the British Medical Journal.
For both sources, reference lists of included studies were
checked. No language or other limitations were imposed.
Chinese text was translated into English by two authors
fluent in Chinese (DZ and PY). Titles were initially
scanned for relevance and abstracts read if titles were
unclear. The full text of papers with no abstract was
viewed and checked for eligibility.
Inclusion and exclusion criteria
We included any papers reporting randomised controlled
trials on all disease groups and all types of interventions,
which were published in 2004, took place in China and
included Chinese citizens. We excluded reports that did
not include any participants from Mainland China. We
excluded papers from Hong Kong and Taiwan where
research and clinical practice are different from those in
the Mainland.
Assessment of quality
The CONSORT statement is an internationally agreed
standard for reporting RCT[11]. It includes recommended
items designed to report the methodology and conduct of
a study that are common to many standard quality assess-
ment checklists. We used or adapted a subset of the CON-
SORT indicators in order to assess both the quality of
reporting and, in those studies where information was
provided, the actual conduct of the study. We also added
some customised indicators in order to extract basic
descriptive information specific to the Chinese papers
(Table 1). We did not use overall quality scores or catego-
ries to judge each paper because the use of summary
scores could be problematic and often obscures individ-
ual aspects of quality [21].
Data extraction and analysis
One reviewer extracted data from all included papers. A
second reviewer independently checked a random sample
of 26% of the papers. Discrepancies were resolved where
possible by discussion, and the sample results compared
with the full results using Kappa scores. Data on the qual-
ity of the included papers were presented in tabular for-
mat accompanied by a critical description.
Results
Search results
Figure 1 describes the results of the search and the identi-
fication of eligible trials. Among 716 identified papers, 29
were initially excluded as they were duplicate publications
of the same study. Only one paper was included for each
study. Twelve were excluded on screening of the titles. Of
the remaining 675 studies, 36 studies were excluded as
they either were not, or could not be confirmed as, RCTs
(Table 2), and 296 were excluded after reading the
abstract. The full text of the remaining 343 papers was
obtained, and finally 307 papers were included as con-Page 2 of 8
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contact author.
Agreement between reviewers
Agreement between the reviewers was good with a kappa
score of greater than 0.7 for the main indicators (funding
source, disease area, choice of comparator interventions,
ethical committee approval, informed consent from par-
ticipants, sample size, randomisation, allocation conceal-
ment, blinding, baseline characteristics, primary
outcomes, loss to follow-up, length of follow-up, statisti-
cal reporting).
Characteristics of the included trials
1. Publication language
Of the 307 included RCT papers, 259 (84%) were written
in Chinese. The remaining 48 papers were published in
English.
2. Nationality of authors
292 (95%) included papers were written by authors based
in Chinese research institutes; the remaining papers were
collaborations between Chinese and foreign researchers.
There were no trials conducted or reported only by foreign
researchers.
3. Funding source
Of the 307 papers, 232 (75.6%) did not report their
sources of funding. Funding was from provincial/munici-
pal and national sources in 38 trials (12.4%) and 23 trials
(7.2%) respectively. Foreign pharmaceutical companies,
universities, international research agencies and the mili-
tary financed five or fewer trials each.
4. Disease area
Fifty (16.3%) of the RCTs focused on diseases of the diges-
tive system (Table 3). The second most published disease
area was disease of the circulatory system with 48 papers
(15.6%), followed by tumours with 42 papers (13.7%)
and diseases of the urogenital system (37 papers
(12.1%)). Nervous system, motor system and respiratory
system diseases each had approximately 5% share of the
total number of trials as did the category of primary pre-
Table 1: Indicators used to describe and evaluate included randomised controlled trials
Indicator Description
Descriptive indicators
1 Publication language Chinese or English
2 Nationality of authors Chinese, international or collaboration
3 Funding source As reported
4 Disease area Simple categories
5 Choice of comparator interventions Placebo/alternative treatment/no treatment
6 Size of trial Number of participants
7 Ethical committee approval Yes/No
8 Informed consent from participants As reported
Quality of reporting: CONSORT indicators
9 Sample size How was sample size determined?
10 Randomisation Was the trial randomised?
11 Allocation concealment What method was used to implement the random allocation sequence?
12 Blinding Whether or not patients and/or investigators were blinded to group assignment
13 Baseline characteristics Were the baseline demographic and clinical characteristics of each group reported
14 Primary outcomes Did they report which outcome was designated as the primary outcome?
15 Length of follow-up As reported
16 Loss to follow-up As reported
17 Statistical reporting Were confidence intervals or p values reported to indicate precision?
Table 2: Reasons for excluding papers
Reason for exclusion Number of papers
Before/after studies 17
Brief report given only 6
Case control study 5
Phase II trial (no control arm) 4
Randomisation not mentioned in full text 2
Allocated by patients' choice 1
Allocated by patients' economic status 1
Total 36Page 3 of 8
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two of the included papers (39.7%) reported studies of
traditional Chinese treatments such as traditional Chinese
medicine (TCM), massage and acupuncture.
5. Choice of comparator interventions
Thirty-nine (12.7%) of the included trials compared
active treatment with a placebo group. Three of these were
randomised controlled crossover trials where participants
were blinded to the order of drug taken. In 179 (58.3%)
trials the new treatment being tested was compared with
an alternative named treatment, and in 79 (25.7%) trials
the new treatment was compared with a treatment
described as the "standard", but with no specific details.
Seven additional studies included a control group receiv-
ing no treatment: three of them were health education
and promotion projects, two of them were health rehabil-
itation and two drug trials. A further three papers
described trials with three different treatment arms: active
treatment, standard treatment and no treatment.
6. Size of the trials
The number of participants in each included trial ranged
from 3 to 19200, with a median of 78.
7&8. Ethical issues (Ethics Committee Approval and Informed 
Consent)
Only 33 (10.8%) of the included Chinese trials reported
approval by an ethics committee. The majority of the
study reports (249 or 81%) did not provide any informa-
tion about informed consent although 54 (17.6%) of
papers stated that the participants did give consent. The
remaining four studies stated that participants were
included in the trial of their own free will.
Quality of reporting
9. Sample size
Only nine (2.9%) of the 307 papers mentioned sample
size calculation.
10&11. Methods of randomisation & allocation concealment
In nearly two-thirds of the included trials (Table 4) the
authors failed to report details of their methods of ran-
domisation. Seventy-three (23.8%) of the trials reported
using a random number table to allocate participants; 13
(4.2%) a random allocation card; 11 (3.6%) a sealed
envelope; 7 (2.3%) computer allocation and 4 (1.3%) the
toss of a coin. Twenty-four trials allocated participants
using visit order that were included in the "not clear"
group. No trial mentioned allocation concealment.
12. Blinding
254 (82.7%) papers provided no information about
blinding of either participants or investigators. In 39
(12.7%) trials, both the investigators and participants
were blinded. In 9 (2.9%) trials the participants were not
blind, and in 5 (1.6%) the investigators were not blinded
to the participants' treatments.
13. Reporting of baseline characteristics
Eighty-nine (29%) of the included papers fully reported
the baseline characteristics of the participants in a separate
table. Two hundred and nine (67%) of the papers
described baseline characteristics using either text or
mixed tables, which also included results. In 9 papers
(2.9%) only age was given in the baseline information,
and in two papers no information was given other than a
statement that the baseline characteristics matched in
both arms.
14. Reporting of primary outcomes
Only 11 (3.6%) of the included trials indicated which
measure was used as the primary outcome; the remainder
merely reported an ordered list of results from which it
was not possible to distinguish which outcome was the
primary.
Table 4: Methods of randomisation
Method Number of papers (%)
Not clear 199 (64.8%)
Random number sheet 73 (23.8%)
Random allocation card 13 (4.2%)
Sealed envelope 11 (3.6%)
Computer allocation 7 (2.3%)
Toss of a coin 4 (1.3%)
Total 307 (100%)
Table 3: Disease area of included trials
Disease area Number of papers Percent
Digestive system diseases 50 16.3
Circulatory system diseases 48 15.6
Tumours* 42 13.7
Urogenital system diseases 37 12.1
Nervous system diseases 16 5.2
Motor system diseases 16 5.2
Healthy population 15 4.9
Respiratory system diseases 15 4.9
Endocrine system diseases 12 3.9
Immune system diseases 9 2.9
Others 47 15.3
Total 307 100.0
*All types/locations of tumoursPage 5 of 8
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Table 5 details the distribution of length-of-follow-up for
participants in the included studies. In 105 (34.2%) of
papers, there was no information about the length of time
for which participants were followed. The mean length of
follow-up (where stated) was 166 days, although the
median (interquartile range) was 56 (8–360) days.
16. Loss-to-follow-up
Over half of the trials (165 studies – 53.7%) reported that
no participants had dropped out (Table 6). Sixty-four per-
cent of all the clinical trials showed a drop out rate of 5%
or less by the end of the study, and overall 70% of all the
trials had a drop out rate lower than 10%. Fifty-seven
(18.6%) studies failed to report dropout rates.
17. Statistical reporting
The majority of the papers (298 trials or 97.1%) con-
ducted t-tests to examine the statistical significance of
their results, and presented p values. In only 20 papers
(6.5%) did the authors use confidence intervals to
describe the uncertainty around their estimates.
Discussion
Key results
Study of trial quality is rare in developing countries, and
tends to focus on limited clinical areas [22,23]. Although
among Chinese publications there are a few paperswhich
describe trial quality in specific journals or fields [13-19],
this is the first systematic study to evaluate the quality of
trial conduct and reporting in a sample which is likely to
be more representative of Chinese RCTs in general.
Our review revealed that the standard of reporting of trials
was generally poor, which concurs with the other pub-
lished reports on Chinese trials [16-19]. For example,
nearly two-thirds failed to report any information on their
methods of randomisation, reinforcing previous work
[18,19]. In the remainder there were various methods of
random allocation, of which about a quarter reported
using a computer-generated method or a random number
table, which are the usually acceptable ways of randomi-
sation. None of the trials discussed allocation conceal-
ment. If the allocation of the patient is not adequate and
fully independent of the enrolling investigator, then this
may allow either conscious or unconscious selection of
participants into the trial, or into particular arms of the
trial, thus introducing selection bias and undermining the
randomisation. The internal validity of a randomised con-
trolled trial has been shown to be directly associated with
a clear description of appropriate methods of random
allocation of participants, and concealment of their allo-
cation [24].
Over 80% of trials provided no information about blind-
ing of either participants or investigators. This confirms
the result observed in a review of RCTs of traditional Chi-
nese medicine[19]. Without blinding the groups may
have been treated differently by the investigator and the
outcomes not measured objectively, thus creating further
assessment bias. Participants aware of their treatment may
behave differently or have particular expectations [8], thus
affecting the results.
Interestingly, among the included Chinese studies in this
review, over half stated that none of their participants
dropped out. This is unusual compared with trials in
countries with more established research programmes,
where a drop-out rate of below 5% is generally considered
a very good result. Over 60% of the trials in this review
reported a drop-out rate of less than 5%, and two-thirds
less than 10%. The reasons behind these very low rates
warrant further investigations.
The reporting of ethical issues was inadequate in the Chi-
nese RCTs. Fewer than 11% of the trials reported having
ethical committee approval, although the latter is a legal
requirement in China [25]. Also, only a minority of the
Chinese studies (17.4%) gave adequate details about
informed consent procedures; a few mentioned that par-
ticipants attended of "their own free will" but the remain-
der made no mention of consent. However, this level
appears better than in a recent review of traditional Chi-
nese medicine trials [19].
Table 6: Dropout rate of included trials
Dropout rate (%) Number of papers Percent Cumulative Percent
Not clear 57 18.6 18.6
0 165 53.7 72.3
0.1–4.9% 27 8.8 81.1
5.0–9.9% 25 8.2 89.3
10.0–24.9% 20 6.5 95.8
>= 25% 13 4.2 100.0
Total 307 100.0
Table 5: Length of follow up of included RCTs (days)
Days of follow-up Number of papers (%)
Not clear 105 (34.2%)
0–30 85 (27.7%)
31–90 43 (14.0%)
91–365 43 (14.0%)
366–3650 31 (10.1%)
Total 307 (100.0%)Page 6 of 8
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tries[26], the standard of reporting in China is lagging
behind, although there are still many fields in Western
countries which have inadequate standards of reporting
[27]. However, the application of the CONSORT state-
ment has demonstrated benefits in improving reporting
[28] and could be expected to do the same in China.
Limitations
Although we undertook a thorough search for eligible
studies using both PubMed and the Journal Series of the
Chinese Medical Association, we may have missed rele-
vant studies not included in the databases. The Journal
Series of 71 Chinese journals comprises the core of the
Chinese medical journals, but only approximately 20% of
the total. RCTs which were not described as such in the
abstract would have been excluded; however it is not clear
how many such false negatives there would have been.
Indeed failure to mention correctly the study design in the
abstract is a mark of poor quality.
Conclusion
Reporting of RCTs in China requires substantial improve-
ment to meet the targets of the CONSORT statement. The
conduct of Chinese RCTs cannot be directly inferred from
the standard of reporting; however without good report-
ing the methods of the trials cannot be clearly ascertained.
Research bodies in China should ensure that the reporting
of RCTs is improved to meet internationally agreed stand-
ards, thereby allowing the conduct of their studies to be
monitored and encouraging high quality standards.
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